Detalhe da pesquisa
1.
Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children.
Br J Clin Pharmacol
; 86(2): 329-337, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658379
2.
Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin®) in paediatric patients under 6 years of age with severe von Willebrand disease.
Blood Transfus
; 21(1): 83-92, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35543677
3.
Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.
Thromb Haemost
; 122(8): 1304-1313, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35642281
4.
Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia.
Thromb Haemost
; 120(6): 957-967, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32392604
5.
Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.
J Thromb Haemost
; 18(8): 1922-1933, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445594
6.
Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.
J Thromb Haemost
; 17(4): 635-644, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30661302